Ontology highlight
ABSTRACT:
SUBMITTER: Bulbul A
PROVIDER: S-EPMC5932412 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
Frontiers in oncology 20180410
First generation or second generation EGFR tyrosine kinase inhibitors are currently the standard of care for the first-line management of non-small cell lung cancer (NSCLC) patients with activating mutations within the kinase domain of the epidermal growth factor receptor gene (1, 2). Resistance to targeted therapy can develop after 9-11 months (3-8). Third generation inhibitors were developed to target the EGFR T790M clone, which is the most common dominant second site resistance mutation after ...[more]